Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971425 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL3031655 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Maleic Acid SCHEMBL10843397 | 0.90 | LMNA (0.48) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Fumaric Acid SCHEMBL10843401 | 0.90 | LMNA (0.48) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL17749334 | 0.87 | LMNA (0.49) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL28303546 | 0.87 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL26668485 | 0.86 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL31381398 | 0.86 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL26668478 | 0.86 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Oxalic Acid SCHEMBL10846796 | 0.86 | HTR2B (0.46) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| EP-0187096-A1 | Arylalcoyloxymethyl-2 morpholines, their preparation and their use as therapeutic agents in the treatment of central nervous system diseases | PIERRE FABRE MEDICAMENT (FR) | 1986-07-09 | — | — | EP | claimed |
| EP-4273143-B1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | DALIAN WZ PROBIOTICS AD HEALTH CO LTD (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240140941-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | DALIAN WZ PROBIOTICS AD HEALTH CO., LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4273143-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Dalian WZ Probiotics AD Health Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-114685456-B | 2, 5-diketopiperazine compound derivative, preparation method thereof, pharmaceutical composition and application thereof | 大连万众益生大健康有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-1028527-C | Process for preparing coumarin derivatives | SANKYO CO (JP) | 1995-05-24 | — | — | CN | disclosed |
| EP-0411912-B1 | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | SANKYO CO (JP) | 1995-04-19 | — | — | EP | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0468231-B1 | Guanidins | HOFFMANN LA ROCHE (CH) | 1994-09-21 | — | — | EP | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0468231-A2 | Guanidins | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-29 | — | — | EP | disclosed |
| CN-1049662-A | Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder | SANKYO CO (JP) | 1991-03-06 | — | — | CN | disclosed |
| EP-0411912-A2 | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | Sankyo Company Limited (JP) | 1991-02-06 | — | — | EP | disclosed |
| EP-0187096-A1 | Arylalcoyloxymethyl-2 morpholines, their preparation and their use as therapeutic agents in the treatment of central nervous system diseases | PIERRE FABRE MEDICAMENT (FR) | 1986-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140941-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | WEE1, WEE2, CYP51A1 | SLC6A2 1841/4885SLC6A4 2161/4885SLC6A3 2042/4885 |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | SLC6A2 4424/4885SLC6A4 4492/4885SLC6A3 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.